Drug Pricing Deals Drive US Manufacturing in 2025
Johnson & Johnson secured a deal with the U.S. government to lower drug prices in exchange for tariff exemptions, expanding on a major policy trend. This theme identifies opportunities among pharmaceutical companies and domestic manufacturers benefiting from government incentives to onshore production.
Your Basket's Financial Footprint
This basket's total market capitalisation is 1,481,736.7483 and is heavily anchored by a small number of very large-cap stocks. That concentration tends to give the basket a large-cap profile with lower expected volatility and more market-like behaviour.
- Large-cap dominance generally implies lower volatility and closer tracking of broad markets, suggesting relatively stable performance and reduced tail risk.
- Use as a core holding for diversified portfolios; not ideal for short-term speculative positions.
- Expect steady, long-term value accumulation rather than rapid, explosive gains; growth tends to be gradual.
LLY: $1.03T
MCK: $100.55B
BMY: $113.80B
- Other
About This Group of Stocks
Our Expert Thinking
The US government is striking deals with major pharmaceutical companies, offering tariff exemptions in exchange for lower drug prices. This policy shift creates significant opportunities for companies involved in domestic pharmaceutical manufacturing and supply chains, as billions in investment flows toward onshoring critical healthcare production.
What You Need to Know
This collection includes two key types of companies: established pharmaceutical giants navigating new pricing agreements, and domestic manufacturers positioned to benefit from reshoring efforts. The trend spans contract manufacturing, logistics, medical devices, and specialised healthcare components essential for expanding US-based production.
Why These Stocks
Each company was handpicked based on their strategic positioning within this evolving landscape. From major pharmaceutical players like Eli Lilly and Bristol-Myers Squibb to specialised manufacturers like West Pharmaceutical Services, these stocks represent direct exposure to government incentives driving healthcare manufacturing back to American shores.
Why You'll Want to Watch These Stocks
Policy-Driven Opportunity
Government incentives are reshaping the pharmaceutical landscape, creating clear winners amongst companies positioned for domestic manufacturing growth.
Billions in New Investment
Major drug makers are committing multi-billion dollar investments to US-based production, driving demand for specialised manufacturing and supply chain partners.
Supply Chain Revolution
The shift from overseas to domestic pharmaceutical manufacturing represents one of the most significant structural changes in healthcare in decades.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Australian Life Insurance: Which Stocks May Benefit?
Zurich Insurance's acquisition of ClearView Wealth underscores a significant consolidation wave in the Australian life insurance market. This development may surface investment opportunities among other potential takeover candidates and the technology firms supporting the industry's evolution.
Amazon Ecosystem: Could This Shift Create New Winners?
Amazon has surpassed Walmart as the largest U.S. company by revenue, signaling a major shift in the American economy. This theme focuses on the ecosystem of companies poised to benefit from the escalating rivalry in e-commerce, cloud computing, and AI-driven logistics.
AI Infrastructure: What's Next After Nvidia Shift?
Nvidia is swapping its $100 billion partnership with OpenAI for a $30 billion direct equity investment, signaling a major recalibration in AI sector financing. This strategic shift creates an investment opportunity among other AI infrastructure firms poised to benefit from OpenAI's diversifying partnerships.